The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults

AIDS Research and Human Retroviruses

Volumn 18, Issue 10, 2002, Pages 685-693

  Kilby, J Michael ^a   Lalezari, Jacob P ^b,c   Eron, Joseph J ^d   Carlson, Margrit ^e   Cohen, Calvin ^f,g   Arduino, Roberto C ^h   Goodgame, Jeffrey C ⁱ   Gallant, Joel E ^j   Volberding, Paul ^c,k,l,m   Murphy, Robert L ⁿ   Valentine, Fred ^o   Saag, Michael S ^a   Nelson, Emily L ^p   Sista, Prakash R ^p   Dusek, Alex ^p  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Quest Clinical Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Community Research Initiative New England ^*  (United States)

^g HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ Central Florida Research Initiative   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k SAN FRANCISCO GENERAL HOSPITAL   (United States)

^l UCSF GIVI Center for AIDS Research   (United States)

^m SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p Trimeris Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENFUVIRTIDE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SLEEP DISORDER; VERTIGO; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PEPTIDE FRAGMENTS; RNA, VIRAL;

EID: 0036066762     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202760072294     Document Type: Article

References (30)

1. Antiretroviral therapy for previously treated patients
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. AIDS across Europe, 1994-98: The EuroSIDA study
5. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
6. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection
7. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier
8. HIV-protease inhibitors
9. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
10. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir
11. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients
12. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
13. Core structure of gp41 from the HIV envelope glycoprotein
14. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion
15. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
16. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
17. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease
18. Antiretroviral drug resistance testing in adult HIV infection: Recommendation s of an International AIDS Society-USA Panel
19. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
20. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
21. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy
22. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
23. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir
24. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
25. Human immunodeficiency virus type 1 coreceptors participate in postentry stages of the virus replication cycle and function in simian immunodeficiency virus infection
26. Mechanisms for HIV-1 entry: Current strategies to interfere with this step
27. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
28. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100
29. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
30. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport